BioInvent’s preclinical research is focused on developing novel immuno-modulatory antibodies for cancer therapy. Such antibodies may significantly improve efficacy of currently available checkpoint inhibitor therapies and/or activate anti-cancer immunity in currently non-responding patients and cancer types.
Strategic collaboration with Pfizer - developing antibodies that act on tumor-associated myeloid cells
In partnership with Pfizer Inc. since December 2016, BioInvent works to identify novel oncology targets and therapeutic antibodies that may either reverse the immunosuppressive activity of tumor-associated myeloid cells or reduce the number of tumor-associated myeloid cells in the tumor. In July 2020 BioInvent announced that the research term under its collaboration and license agreement with Pfizer had been further extended until the end of 2020.
In December 2020 BioInvent announced that Pfizer had selected antibodies directed at a previously selected target. The selection of these antibodies triggered a payment from Pfizer to BioInvent of $3 million
BioInvent announced in July 2019 selection of the first target and in December 2019 the second target discovered by BioInvent’s proprietary F.I.R.S.T™ technology platform under the collaboration with Pfizer Inc. The selection of targets triggered two payments from Pfizer to BioInvent of $0.3 million.
BioInvent is eligible for potential future development milestones in excess of $100 million if one antibody is developed through to commercialization. The Company could also receive up to double digit royalties related to product sales. In exchange, Pfizer will have the right to develop and commercialize any antibodies generated from this agreement.
BioInvent received an upfront payment of $3 million when the agreement was signed in December 2016, and research funding has been received for the period 2017-2020. Pfizer also made a $6 million equity investment in new shares of BioInvent when the agreement was signed.
Developing antibodies that act on regulatory T cells (Tregs) via novel or validated targets
Tregs can substantially inhibit various immune responses, enabling tumor cells to escape detection. BioInvent is utilizing its F.I.R.S.T™ platform to identify and characterize monoclonal antibodies to cancer-associated Treg targets in a function-first, target-agnostic, manner. The company is also pursuing differentiated antibodies to known targets through novel mechanisms and pathways.